Kornitzer Capital Management Inc. KS Has $5.47 Million Holdings in DexCom, Inc. $DXCM

Kornitzer Capital Management Inc. KS lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,461 shares of the medical device company’s stock after selling 11,856 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in DexCom were worth $5,473,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. PFA Pension Forsikringsaktieselskab acquired a new stake in shares of DexCom during the 4th quarter worth approximately $23,168,000. Horizon Investments LLC grew its holdings in shares of DexCom by 16.6% during the 4th quarter. Horizon Investments LLC now owns 14,367 shares of the medical device company’s stock worth $954,000 after purchasing an additional 2,043 shares in the last quarter. New York State Teachers Retirement System grew its holdings in shares of DexCom by 0.9% during the 4th quarter. New York State Teachers Retirement System now owns 302,595 shares of the medical device company’s stock worth $20,083,000 after purchasing an additional 2,801 shares in the last quarter. Laurel Wealth Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth approximately $48,000. Finally, Cardinal Capital Management grew its holdings in shares of DexCom by 14.8% during the 4th quarter. Cardinal Capital Management now owns 56,063 shares of the medical device company’s stock worth $3,721,000 after purchasing an additional 7,216 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $61.35 on Friday. The business’s fifty day moving average price is $65.87 and its two-hundred day moving average price is $66.41. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The stock has a market capitalization of $23.67 billion, a price-to-earnings ratio of 26.22, a price-to-earnings-growth ratio of 1.20 and a beta of 1.40. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 34.18% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the business posted $0.32 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. As a group, analysts predict that DexCom, Inc. will post 2.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a report on Tuesday, March 24th. Mizuho set a $75.00 price objective on DexCom in a report on Friday. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday. Finally, Citigroup upped their price target on DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $83.73.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.